-DOCSTART- -X- O
Background. -X- _ O
The -X- _ O
high -X- _ O
burden -X- _ O
of -X- _ O
respiratory -X- _ O
syncytial -X- _ O
virus -X- _ O
( -X- _ O
RSV -X- _ O
) -X- _ O
-associated -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
makes -X- _ O
vaccine -X- _ O
development -X- _ O
a -X- _ O
priority. -X- _ O
Methods. -X- _ O
As -X- _ O
part -X- _ O
of -X- _ O
an -X- _ O
efficacy -X- _ O
trial -X- _ O
of -X- _ O
pandemic -X- _ B-Intervention
influenza -X- _ I-Intervention
vaccines -X- _ I-Intervention
( -X- _ I-Intervention
NCT01051661 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
RSV -X- _ O
epidemiology -X- _ O
in -X- _ O
healthy -X- _ B-Patient
children -X- _ I-Patient
aged -X- _ I-Patient
6 -X- _ I-Patient
months -X- _ I-Patient
to -X- _ I-Patient
< -X- _ I-Patient
10 -X- _ I-Patient
years -X- _ I-Patient
at -X- _ O
first -X- _ B-Intervention
vaccination -X- _ I-Intervention
with -X- _ I-Intervention
influenza-like -X- _ I-Intervention
illness -X- _ I-Intervention
( -X- _ I-Intervention
ILI -X- _ I-Intervention
) -X- _ I-Intervention
was -X- _ O
evaluated -X- _ O
in -X- _ O
Australia -X- _ B-Comparison
, -X- _ I-Comparison
Brazil -X- _ I-Comparison
, -X- _ I-Comparison
Colombia -X- _ I-Comparison
, -X- _ I-Comparison
Costa -X- _ I-Comparison
Rica -X- _ I-Comparison
, -X- _ I-Comparison
Mexico -X- _ I-Comparison
, -X- _ I-Comparison
the -X- _ I-Comparison
Philippines -X- _ I-Comparison
, -X- _ I-Comparison
Singapore -X- _ I-Comparison
, -X- _ I-Comparison
and -X- _ I-Comparison
Thailand -X- _ I-Comparison
between -X- _ I-Comparison
February -X- _ I-Comparison
2010 -X- _ I-Comparison
and -X- _ I-Comparison
August -X- _ I-Comparison
2011. -X- _ I-Comparison
Active -X- _ O
surveillance -X- _ O
for -X- _ O
ILI -X- _ O
was -X- _ O
conducted -X- _ O
for -X- _ O
approximately -X- _ O
1 -X- _ O
year -X- _ O
, -X- _ O
with -X- _ O
nasal -X- _ O
and -X- _ O
throat -X- _ O
swabs -X- _ O
analyzed -X- _ O
by -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction. -X- _ O
The -X- _ O
prevalence -X- _ O
and -X- _ O
incidence -X- _ O
of -X- _ O
RSV -X- _ O
among -X- _ O
ILI -X- _ O
episodes -X- _ O
were -X- _ O
calculated. -X- _ O
Results. -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
6266 -X- _ O
children -X- _ O
were -X- _ O
included -X- _ O
, -X- _ O
of -X- _ O
whom -X- _ O
2421 -X- _ O
experienced -X- _ O
3717 -X- _ O
ILI -X- _ O
episodes -X- _ O
with -X- _ O
a -X- _ O
respiratory -X- _ B-Outcome
sample -X- _ I-Outcome
available. -X- _ I-Outcome
RSV -X- _ B-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
for -X- _ I-Outcome
359 -X- _ I-Outcome
ILI -X- _ I-Outcome
episodes -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
prevalence -X- _ I-Outcome
of -X- _ I-Outcome
9.7 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
: -X- _ I-Outcome
8.7–10.7 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
The -X- _ B-Outcome
highest -X- _ I-Outcome
prevalence -X- _ I-Outcome
was -X- _ I-Outcome
in -X- _ I-Outcome
children -X- _ I-Outcome
aged -X- _ I-Outcome
12–23 -X- _ I-Outcome
or -X- _ I-Outcome
24–35 -X- _ I-Outcome
months -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
countries -X- _ I-Outcome
except -X- _ I-Outcome
the -X- _ I-Outcome
Philippines -X- _ I-Outcome
, -X- _ I-Outcome
where -X- _ I-Outcome
it -X- _ I-Outcome
was -X- _ I-Outcome
in -X- _ I-Outcome
children -X- _ I-Outcome
aged -X- _ I-Outcome
6–11 -X- _ I-Outcome
months. -X- _ I-Outcome
The -X- _ B-Outcome
incidence -X- _ I-Outcome
of -X- _ I-Outcome
RSV-associated -X- _ I-Outcome
ILI -X- _ I-Outcome
was -X- _ I-Outcome
7.0 -X- _ I-Outcome
( -X- _ I-Outcome
6.3–7.7 -X- _ I-Outcome
) -X- _ I-Outcome
per -X- _ I-Outcome
100 -X- _ I-Outcome
person-years -X- _ I-Outcome
( -X- _ I-Outcome
PY -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Eighty-eight -X- _ B-Outcome
ILI -X- _ I-Outcome
episodes -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
hospitalization -X- _ I-Outcome
, -X- _ I-Outcome
of -X- _ I-Outcome
which -X- _ I-Outcome
8 -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
RSV -X- _ I-Outcome
( -X- _ I-Outcome
prevalence -X- _ I-Outcome
9.1 -X- _ I-Outcome
% -X- _ I-Outcome
[ -X- _ I-Outcome
4.0–17.1 -X- _ I-Outcome
] -X- _ I-Outcome
; -X- _ I-Outcome
incidence -X- _ I-Outcome
0.2 -X- _ I-Outcome
[ -X- _ I-Outcome
0.1–0.3 -X- _ I-Outcome
] -X- _ I-Outcome
per -X- _ I-Outcome
100 -X- _ I-Outcome
PY -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
The -X- _ B-Outcome
incidence -X- _ I-Outcome
of -X- _ I-Outcome
RSV-associated -X- _ I-Outcome
ILI -X- _ I-Outcome
resulting -X- _ I-Outcome
in -X- _ I-Outcome
medical -X- _ I-Outcome
attendance -X- _ I-Outcome
was -X- _ I-Outcome
6.0 -X- _ I-Outcome
( -X- _ I-Outcome
5.4–6.7 -X- _ I-Outcome
) -X- _ I-Outcome
per -X- _ I-Outcome
100 -X- _ I-Outcome
PY. -X- _ I-Outcome
RSV -X- _ O
B -X- _ O
subtypes -X- _ O
were -X- _ O
observed -X- _ O
more -X- _ O
frequently -X- _ O
than -X- _ O
A -X- _ O
subtypes. -X- _ O
Conclusions. -X- _ O
Active -X- _ O
surveillance -X- _ O
demonstrated -X- _ O
the -X- _ O
considerable -X- _ O
burden -X- _ O
of -X- _ O
RSV-associated -X- _ O
illness -X- _ O
that -X- _ O
would -X- _ O
not -X- _ O
be -X- _ O
identified -X- _ O
through -X- _ O
hospital-based -X- _ O
surveillance -X- _ O
, -X- _ O
with -X- _ O
a -X- _ O
substantial -X- _ O
part -X- _ O
of -X- _ O
the -X- _ O
burden -X- _ O
occurring -X- _ O
in -X- _ O
older -X- _ O
infants -X- _ O
and -X- _ O
children -X- _ O
. -X- _ O

